Experimental study on effects of deferoxamine mesilate in ameliorating cisplatin-induced nephrotoxicity
- 52 Downloads
Purpose: Cisplatin (CCDP), an indispensable agent of several chemotherapy protocols, has serious dose limiting side effects, including nephrotoxicity. In this experimental study, we used deferoxamine mesilate (DFO), an iron chelating agent, to ameliorate cisplatin-induced nephrotoxicity. Materials and methods: Sixty adult male bulb-c mice were divided in 6 equal groups. Group 1 received distilled water, group 2 received 100 mg/kg DFO, group 3 received 0.9 mg/kg CCDP, group 4 received 100 mg/kg DFO one hour before 0.9 mg/kg CCDP, group 5 received 1.8 mg/kg CCDP, and group 6 received 200 mg/kg DFO one hour before 1.8 mg/kg CCDP transperitoneally for 10 days. The next day, blood and urine samples were obtained, and all the animals were sacrificed, the kidneys and testes were removed, and histopathologic and biochemical analyses were performed. Results: Low-dose and high-dose CCDP treated mice had significantly more extensive proximal tubular degeneration (p < 0.001) when compared to control animals. Moreover, these changes were significantly less extensive in the mice taking DFO than mice taking CCDP. DFO showed no effect on cisplatin induced testicular histopathology. The cisplatin administration significantly increased the serum urea and plasma creatinin concentrations, and DFO administration prior to CCDP significantly decreased serum urea and plasma creatinin concentrations. Conclusion: Our findings suggest that DFO administration may be safe and useful for ameliorating cisplatin-induced nephrotoxicity.
Unable to display preview. Download preview PDF.
- 1.Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozenweig M, Young RC, Muggia F. Toxic effects of cisdichlorodiammine platinum in man. Cancer Treat Rep 1979; 63: 1527–1531.Google Scholar
- 2.Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyssac PP. Renal tubular function in patients treated with high dose cisplatin. Clin Pharmacol Ther 1988; 44: 164–172.Google Scholar
- 3.Badary OA, Nagi MN, Al-Shabanah OA, Al-Sawaf HA, Al-Sohaibani MO, Al-Bekairi AM. Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity. Can J Physiol Pharmacol 1997; 75: 1356–1361.Google Scholar
- 4.Novogrodsky A, Weisspapir M, Patya M, Meshorer A, Vanichkin A. Tyrphostin 4-nitrobenzylidene malononitrile reduces chemotherapy toxicity without impairing efficacy. Cancer Res 1998; 58: 2397–403.Google Scholar
- 5.Watanabe H, Kanno H. [Experimental studies of the protective effect of deferoxamine mesilate on cisplatin induced toxicity]. Nippon Jibiinkoka Gakkai Kaiho 1998; 101: 967–978.Google Scholar
- 6.Hanigan MH, Gallagher BC, Taylor PT. Cisplatin nephrotoxicity: Inhibition of ?-glutamyl transpeptidase blocks the nephrotoxicity of cisplatin without reducing platinium concentration in the kidney. Am J Obstet Gynecol 1996; 175: 270–274.Google Scholar
- 7.Kocao?glu S, Karan A, Berkan T, Başdemir G. Acute acetaminophene nephrotoxicity and urinary gamma-glutamyl transferase activity in rats. Drug Metabol Drug Interact 1997; 14: 47–54.Google Scholar
- 8.Baliga R, Zhang Z, Baliga M, Ueda N, Shah V. Role of cytochrome p-450 as a source of catalytic iron in cisplatin-induced nephrotoxicity. Kidney International 1998; 54: 1562–1569.Google Scholar
- 9.Leibbrandt MET, Wolfgang GHI, Metz AL, Ozobia AA, Haskins JR. Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney International 1995; 48: 761–770.Google Scholar
- 10.Kersten L, Braunlich H, Keppler BK, Gliesing C, Wendelin M, Westphal J. Comparative nephrotoxicity of some antitumoractive platinum and ruthenium complexes in rats. J Appl Toxicol 1998; 18: 93–101.Google Scholar